angiotensin ii, des-phe(8)- has been researched along with spironolactone in 2 studies
| Studies (angiotensin ii, des-phe(8)-) | Trials (angiotensin ii, des-phe(8)-) | Recent Studies (post-2010) (angiotensin ii, des-phe(8)-) | Studies (spironolactone) | Trials (spironolactone) | Recent Studies (post-2010) (spironolactone) |
|---|---|---|---|---|---|
| 1,533 | 21 | 995 | 7,222 | 960 | 1,923 |
| Protein | Taxonomy | angiotensin ii, des-phe(8)- (IC50) | spironolactone (IC50) |
|---|---|---|---|
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Estrogen receptor | Homo sapiens (human) | 5.702 | |
| Glucocorticoid receptor | Homo sapiens (human) | 4.0745 | |
| Progesterone receptor | Homo sapiens (human) | 1.675 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0315 | |
| Androgen receptor | Homo sapiens (human) | 0.3585 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.406 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 6.92 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alves, PH; Castro, CH; Colugnati, DB; Macedo, LM; Mendes, EP; Nunes, AD; Pedrino, GR; Santos, RA; Souza, AP | 1 |
| Casarini, DE; Sanches Aragão, D; Stoll, D; Yokota, R | 1 |
2 other study(ies) available for angiotensin ii, des-phe(8)- and spironolactone
| Article | Year |
|---|---|
Influence of antihypertensive drugs on aortic and coronary effects of Ang-(1-7) in pressure-overloaded rats.
Topics: Amlodipine; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Abdominal; Blood Pressure; Calcium Channel Blockers; Captopril; Coronary Vessels; Losartan; Male; Mineralocorticoid Receptor Antagonists; Models, Animal; Peptide Fragments; Rats, Wistar; Reproducibility of Results; Spironolactone; Time Factors; Vasoconstriction; Vasodilation | 2017 |
Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1-7)/MAS receptor axes in human mesangial cells.
Topics: Aldosterone; Angiotensin I; Angiotensin-Converting Enzyme 2; Cells, Cultured; Glycosylation; Humans; Mesangial Cells; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled; Spironolactone; Vesicular Transport Proteins | 2019 |